Original articleImmunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study
Section snippets
Data source
A nationwide population-based case-control study was performed using the Taiwanese National Health Insurance Research Database (NHIRD). The Taiwanese National Health Insurance program is a mandatory universal health insurance scheme that covers more than 98% of Taiwan's 23 million population. The NHIRD database contains the demographic information, diagnostic codes, inpatient and outpatient physician claims, and prescription drug claims from this health insurance system, and has been used
Clinical features of patients
A total of 10,581 patients with SLE were identified from the Catastrophic Illness Registry of the NHIRD. In all, 255 patients with a diagnosis of HZ before the first diagnosis of SLE were excluded. In addition, 1465 patients with rheumatoid arthritis; 339 patients with systemic sclerosis, dermatomyositis, or polymyositis; and 112 patients with psoriasis were excluded. The SLE cohort therefore consisted of 8410 patients; of these, 1555 developed HZ infection. The 1555 patients with SLE who
Discussion
Previous studies investigating the relationship between immunosuppressive medication use and development of HZ in patients with SLE were limited and produced conflicting results.9, 10, 11, 12, 13, 14, 15, 16 Using a large nationwide population-based database, we found that patients with SLE receiving various types of immunosuppressive medications (including systemic corticosteroids, hydroxychloroquine, cyclophosphamide, azathioprine, methotrexate, and mycophenolate mofetil) had significantly
References (41)
Herpes zoster: epidemiology, natural history, and common complications
J Am Acad Dermatol
(2007)Immune senescence and vaccines to prevent herpes zoster in older persons
Curr Opin Immunol
(2012)- et al.
Association between antidiabetic drugs and psoriasis risk in diabetic patients: results from a nationwide nested case-control study in Taiwan
J Am Acad Dermatol
(2015) - et al.
Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study
J Am Acad Dermatol
(2014) - et al.
Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan
J Am Acad Dermatol
(2013) - et al.
Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment
Lancet
(2013) - et al.
The case for Zostavax vaccination in systemic lupus erythematosus
Vaccine
(2013) - et al.
Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic
Am J Transplant
(2012) - et al.
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients
Blood
(2014) Cell-mediated immunity to varicella-zoster virus
J Infect Dis
(1992)
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine
J Infect Dis
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine
J Infect Dis
VZV T cell-mediated immunity
Curr Top Microbiol Immunol
High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis
Ann Rheum Dis
Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus
J Rheumatol
Lymphopenia, anti-Ro/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus
Acta Derm Venereol
Increased incidence of herpes zoster among patients with systemic lupus erythematosus
Lupus
Association of herpes zoster infection with clinical characteristics and MBL2 gene polymorphisms in Chinese children with systemic lupus erythematosus
Pediatr Infect Dis J
Herpes zoster in systemic lupus erythematosus
J Rheumatol
Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome
J Rheumatol
Cited by (30)
Lupus and infections
2018, Dubois' Lupus Erythematosus and Related SyndromesIncidence and Prevention of Herpes Zoster Reactivation in Patients with Autoimmune Diseases
2017, Rheumatic Disease Clinics of North AmericaCitation Excerpt :Among patients with SLE, use of prednisone (hazard ratio [HR], 2.29; 95% confidence interval [CI], 1.24–4.23) and mycophenolate mofetil (HR, 5.0; 95% CI, 1.4–17.6) within the past 6 months placed patients at higher risk for developing HZ. Another case-control study of HZ in SLE performed in a nationwide sample from Taiwan found that use of any immunomodulatory or immunosuppressant medication, including hydroxychloroquine, increased the risk of HZ in a dose-dependent manner.24 Studies are generally mixed, with some showing HZ incidence increasing with immunosuppression, whereas others found a high rate of HZ among patients with SLE with quiescent disease on little to no immunosuppression.12,15,21,25
Vaccination updates and special considerations for systemic lupus erythematosus patients
2024, Current Opinion in RheumatologyExploring machine learning methods for predicting systemic lupus erythematosus with herpes
2023, International Journal of Rheumatic Diseases
Supported by grants from Kaohsiung Medical University Hospital (KMUH103-3T02, KMUH104-4T01, KMUH104-4R49).
Conflicts of interest: None declared.